The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3β pathway
Abstract
Alzheimer's disease (AD) is the progressive development of fatal neurodegenerative diseases. Owing to the unclearness of the pathogenesis of AD and the failure of the drug to cross the blood-brain barrier (BBB), there is currently a lack of effective diagnostic and therapeutic approaches in the treatment of AD. The aim of this study was to design exosomes (Exo) as a specifically designed carrier able to carry curcumin (cur) to prevent neuronal death in vitro and in vivo to alleviate the AD symptoms. Our results demonstrated that Exo improved the solubility and bioavailability of cur and increased drug penetration across the BBB by specific active targeting between Exo, inheriting the lymphocyte function-associated antigen 1 (LFA-1) and endothelial intercellular adhesion molecule 1 (ICAM-1). Exosomes derived from curcumin-treated (primed) cells (Exo-cur) can better prevent the death of neurons in vitro and in vivo to relieve the symptoms of AD by inhibiting phosphorylation of the Tau protein through activating the AKT/GSK-3β pathway. Our results suggested that Exo-cur featured highly effective BBB-crossing via receptor-mediated transcytosis to access brain tissues and inhibited Tau phosphorylation, holding great potential in improving targeted drug delivery and the recovery of neuronal function in AD therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, it enhanced curcumin solubility, stability, and bioavailability, and curcumin exhibited a slow and smooth release profile.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“Enhanced brain penetration via RMT was also observed, with a 6.5 times higher brain concentration compared to free curcumin.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“Western plot analysis confirmed the inheritance of lymphocyte function-associated antigen 1 (LFA-1) from their parental cells, a protein that interacts with the endothelial intercellular adhesion molecule 1 (ICAM-1), used for BBB crossing.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“No significant cytotoxicity was reported; in vivo, higher hippocampus accumulation was observed, and a reduction in OA-induced neuronal injury, cytotoxicity, and tau phosphorylation was confirmed.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“The MWM test revealed an amelioration of learning and memory abilities by presenting shorter escape latencies, spatially oriented swimming behavior, and more time in the targeted quadrant.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“Finally, naïve exosomes also reduced OA-induced consequences and inhibited microglia activation and neuronal cell apoptosis.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Using exosomes, naturally-equipped nanocarriers, for drug delivery
Batrakova, E. V., & Kim, M. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.030 · Cited by 1,041
(2016) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 874
Research works printed but not linked: 3
- M. Prince , A.Comas-Herrera , M.Knapp , M.Guerchet and M.Karagiannidou , in Proceedings of the World Alzheimer Report at Alzheimer's Disease International , London, UK , September, 2016
- Holtzman, 2011, Sci. Transl. Med., 3, 77sr1
- Johnsen, 2014, Biochim. Biophys. Acta, 1846, 75
Cited by
Sorted by citations
Exosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W., Chen, C., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 642
Exosome engineering: Current progress in cargo loading and targeted delivery
Fu, S., Wang, Y., Xia, X., & Zheng, J. C. (2020) · NanoImpact · doi:10.1016/j.impact.2020.100261 · Cited by 444
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Extracellular vesicles: a rising star for therapeutics and drug delivery
Du, S., Guan, Y., Xie, A., Yan, Z., Gao, S., Li, W., Rao, L., Chen, X., & Chen, T. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01973-5 · Cited by 343
Chen, H.-X., Liang, F.-C., Gu, P., Xu, B.-L., Xu, H.-J., Wang, W.-T., Hou, J.-Y., Xie, D.-X., Chai, X.-Q., & An, S.-J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2473-5 · Cited by 319
Metadata
- Authors
- Wang, H., Sui, H., Zheng, Y., Jiang, Y., Shi, Y., Liang, J., & Zhao, L.
- Affiliations
- Jinzhou Medical University (CN)
- Corresponding author
- Shi, Yijie
- Liang, Jia
- Zhao, Liang
- Venue
- Nanoscale
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 11
- Issue
- 15
- Pages
- 7481-7496
- ISSN
- 2040-3364 (ISSN-L)
- 2040-3372
- OpenAlex
- W2923362583
- Cited by
- 324
- References
- 48
- Citations by year
- 2026: 26 · 2025: 51 · 2024: 48 · 2023: 63 · 2022: 45 · 2021: 51 · 2020: 32 · 2019: 8
- FWCI
- 23.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nanoscale (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81501017, 81502484)
- Natural Science Foundation of Liaoning Province (201602337)
- Department of Education of Liaoning Province (JYTQN201719)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
- Keywords
- curcumin, exosomes, Alzheimer's disease, tau hyperphosphorylation, blood-brain barrier penetration, transcytosis, drug delivery, neuronal cell death, cognitive function
- MeSH terms
- RAW 264.7 Cells, Glycogen Synthase Kinase 3 beta, Alzheimer Disease, Animals, Cognition, Curcumin, Disease Models, Animal, Drug Carriers, Male, Phosphorylation, tau Proteins, Rats, Sprague-Dawley, Proto-Oncogene Proteins c-akt, Mice, Rats, Exosomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
